02/22/2005 13:11 FAX 9254728893

Atty Docket No. 15280W-003000

PTO FAX NO.:

703-872-9306

571-273-0609

RECITY 10 CENTRAL FAX CENTER

ATTENTION:

Examiner Badio Group Art Unit 1616 FEB 2 2 2 2000

OFFICIAL COMMUNICATION

FOR THE PERSONAL ATTENTION OF

EXAMINER BADIO

CERTIFICATION OF FACSIMILE TRANSMISSION

I hereby certify that the following documents, in re Application of Hyun K. Kim et al., Application No. 09/526,855, filed March 17, 2000, for STRUCTURAL MODIFICATION OF 19-NORPROGESTERONE I: 17-ALPHA-SUBSTITUTED-11-BETA-SUBSTITUTED-4-ARYL AND 21-SUBSTITUTED 19-NORPREGNADIENEDIONE AS NEW ANTIPROGESTATIONAL AGENTS, is being facsimile transmitted to the Patent and Trademark Office on the date shown below.

Documents Attached

1. Transmittal Form

Number of pages being transmitted, including this page: 5

Dated: February 22, 2005

Linda/Shaffer

PLEASE CONFIRM RECEIPT OF THIS PAPER BY RETURN FACSIMILE AT (415) 576-0300

TOWNSEND and TOWNSEND and CREW LLP Two Embarcadero Center, 8th Floor San Francisco, CA 94111-3834 Telephone: (415) 576-0200, Fax: (415) 576-0300

60427099 v1

I hereby certify that this correspondence is being deposited by facsimile to Art Unit 1616 at 703-872-9306

PATENT Attorney Docket No.: 15280W-003000

Client Ref. No.: E-155-1999

RECEIVED CENTRAL FAX CENTER

FEB 2 2 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Hyun K. Kim et al.

Application No.: 09/526,855

Filed: March 17, 2000

For: STRUCTURAL MODIFICATION OF 19-NORPROGESTERONE I: 17-ALPHA-SUBSTITUTED-11-BETA-SUBSTITUTED-4-ARYL AND 21-SUBSTITUTED 19-NORPREGNADIENEDIONE AS NEW ANTIPROGESTATIONAL AGENT

Customer No.: 20350

Confirmation No. 3023

Barbara P. Badio Examiner:

Technology Center/Art Unit: 1616

CORRECTED AMENDMENT AFTER ALLOWANCE UNDER 37 CFR § 1.312(a)

Mail Stop AF

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In response to a telephone inquiry of Examiner Badio in which it was noted that there was a typographical error in the "Amendments to the Specification" in the previously filed Amendment After Allowance, Applicants amend the above-identified application as follows:

Amendments to the Specification begin on page 2 of this paper.

Remarks/Arguments begin on page 3 of this paper.